The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab.
about
Combination Radioimmunotherapy Approaches and Quantification of Immuno-PETIn-vivo biodistribution and safety of 99mTc-LLP2A-HYNIC in canine non-Hodgkin lymphomaSubsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma.Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomabRadioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab.Pharmacokinetics and dosimetry of (111)In/(188)Re-labeled PEGylated liposomal drugs in two colon carcinoma-bearing mouse models.Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.A review of tositumomab and I(131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma.Standard Operating Procedure for Prospective Individualised Dosimetry for ([131])I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma.Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma.Iodine 131 tositumomab in the treatment of non-Hodgkin's lymphoma.Imaging in targeted delivery of therapy to cancer.Dosimetric evaluation of nanotargeted (188)Re-liposome with the MIRDOSE3 and OLINDA/EXM programs.Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy.Radioimmunotherapy for Non-Hodgkin's Lymphoma.
P2860
Q26747546-4F5F1EA6-CA1E-4598-B9EE-71D4E43E8B67Q27305229-B2A9C622-6763-401A-B5DC-FF5329064875Q33369640-0BF2C71A-2D4C-48AD-B2F6-0CED85956927Q33392939-634E1B2B-49FE-4901-8044-5D95EA03DB1FQ34631795-A4BF2ADA-F946-4DF1-A274-46F9B272E0D4Q35084128-D44D0961-8B5D-4962-9DBD-1A1D0EB51A58Q35780034-408F390D-B2AB-490B-8DF0-0DE716104166Q36150468-144DFD53-1D66-4F5C-9079-D777249B2177Q36563416-7BEA465B-49EA-4C10-AF15-6135487887D5Q36684500-21F4A860-A2FF-4BAC-A46A-ABDF7B16ECC6Q36839758-BE3CD414-BD39-460B-BEB0-70BE6AF41B74Q37617137-EFE12314-BE86-4244-9EB9-FBCC7CF4579FQ39373508-A7F3FF35-0D73-4F8F-BF07-BFD51B732C91Q50754917-00BC2B88-B388-4356-88B6-265C78855F15Q55041225-95181132-1586-47E7-8D4F-B683A4615E13
P2860
The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
The clinical importance of dos ...... and iodine I 131 tositumomab.
@ast
The clinical importance of dos ...... and iodine I 131 tositumomab.
@en
type
label
The clinical importance of dos ...... and iodine I 131 tositumomab.
@ast
The clinical importance of dos ...... and iodine I 131 tositumomab.
@en
prefLabel
The clinical importance of dos ...... and iodine I 131 tositumomab.
@ast
The clinical importance of dos ...... and iodine I 131 tositumomab.
@en
P356
P1433
P1476
The clinical importance of dos ...... and iodine I 131 tositumomab.
@en
P2093
Richard L Wahl
P356
10.1053/SONC.2003.23799
P433
P577
2003-04-01T00:00:00Z